Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
S1900C
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
- NCT04173507 ↗
- Completed
- SWOG Cancer Research Network
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on S1900C (talazoparib plus avelumab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on S1900C so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma; Recurrent Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
- Interventions
- Avelumab; Talazoparib; Talazoparib Tosylate
- Arms
- Treatment (talazoparib, avelumab) · Experimental
- Enrollment
- 47
- Primary outcomes
- Objective Response Rate (ORR)
- Disease Control Rate at 12 Weeks (DCR12)
- Sponsor
- SWOG Cancer Research Network with National Cancer Institute (NCI)
- Start
- Feb 14, 2020
- Primary completion
- Nov 24, 2021
- Results posted
- Yes
- Registry record
- NCT04173507 · updated Sep 3, 2024